Gilead Sciences Inc. closed 8.32% below its 52-week high of $119.96, which the company reached on March 10th.

The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...

Margaret Atwood’s chilling world of Gilead returns in The Testaments, the long-anticipated sequel to her groundbreaking novel ...

The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...

The firm’s analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Goldman Sachs analyst ...

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...

Let’s just say you wake up one morning in The Handmaid’s Tale universe, stuck inside the color-coded hellscape that is Gilead ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: ...

The ultraconservative dictatorship in which the series based on Margaret Atwood’s novel is set is becoming less and less unthinkable ...